Chimeric antigen receptor (CAR) T-cell immunotherapy following autologous stem cell transplantation (ASCT) is a promising method for refractory or relapsed multiple myeloma, but explicit data for central nervous system lymphoma (CNSL) are lacking. Here, we treated 13 CNSL patients with ASCT sequential CD19/22 CAR T-cell infusion and simultaneously evaluated the clinical efficacy and toxicity. The 13 CNSL patients analyzed included four primary CNSL and nine secondary CNSL patients. Patients 1 and 10, who had complete remission status before enrollment, maintained clinical efficacy without recurrence. Nine of the remaining 11 patients responded to our protocol with a median durable time of 14.03 months, and the overall response and complete remission rate were 81.81% and 54.55%, respectively. No patient suffered grades 3–4 cytokine-release syndrome (CRS), and only patient 10 experienced severe immune effector cell-associated neurotoxicity syndrome (ICANS). In addition, increases in serum ferritin and interleukin-6 levels were often accompanied by CRS and ICANS. After a median follow-up time of 14.20 months, the estimated 1-year progression-free survival and overall survival rates were 74.59% and 82.50%, respectively. Sequential CD19/22 CAR T-cell immunotherapy following ASCT as a novel method for CNSL appears to have encouraging long-term efficacy with relatively manageable side effects.

自体干细胞移植 (ASCT) 后的嵌合抗原受体 (CAR) T 细胞免疫治疗是治疗难治性或复发性多发性骨髓瘤的一种有前途的方法，但缺乏中枢神经系统淋巴瘤 (CNSL) 的明确数据。在这里，我们用 ASCT 连续 CD19/22 CAR T 细胞输注治疗了 13 名 CNSL 患者，同时评估了临床疗效和毒性。分析的 13 名 CNSL 患者包括 4 名原发性 CNSL 和 9 名继发性 CNSL 患者。入组前完全缓解状态的患者 1 和 10 保持临床疗效，无复发。其余 11 名患者中有 9 名对我们的方案有反应，中位持续时间为 14.03 个月，总体反应率和完全缓解率分别为 81.81% 和 54.55%。没有患者出现 3-4 级细胞因子释放综合征 (CRS)，只有 10 号患者出现严重的免疫效应细胞相关神经毒性综合征 (ICANS)。此外，血清铁蛋白和白细胞介素 6 水平的升高通常伴有 CRS 和 ICANS。中位随访时间为 14.20 个月后，估计的 1 年无进展生存率和总生存率分别为 74.59% 和 82.50%。ASCT 后的连续 CD19/22 CAR T 细胞免疫治疗作为 CNSL 的一种新方法，似乎具有令人鼓舞的长期疗效和相对可控的副作用。20个月，估计1年无进展生存率和总生存率分别为74.59%和82.50%。ASCT 后的连续 CD19/22 CAR T 细胞免疫治疗作为 CNSL 的一种新方法，似乎具有令人鼓舞的长期疗效和相对可控的副作用。20个月，估计1年无进展生存率和总生存率分别为74.59%和82.50%。ASCT 后的连续 CD19/22 CAR T 细胞免疫治疗作为 CNSL 的一种新方法，似乎具有令人鼓舞的长期疗效和相对可控的副作用。